<DOC>
	<DOCNO>NCT01360827</DOCNO>
	<brief_summary>The primary purpose trial ass safety tolerability EMD 1201081 , novel immunomodulatory agent agonist TLR9 , combination 5-FU/cisplatin cetuximab first line treatment patient recurrent/metastatic squamous cell carcinoma head neck , determine maximum tolerate dose ( MTD ) among dose level .</brief_summary>
	<brief_title>EMD 1201081 + 5-FU + Cisplatin + Cetuximab Subjects With Recurrent / Metastatic Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis squamous cell carcinoma head neck ( SCCHN ) . Recurrent and/or metastatic SCCHN , suitable local therapy . At least 1 measurable lesion either computerize tomography ( CT ) scan magnetic resonance imaging ( MRI ) ( accord RECIST 1.0 ) . Karnofsky performance status ( KPS ) ≥ 70 / Eastern Cooperative Oncology Group performance status ( ECOG PS ) 0 1 trial entry . Prior systemic chemotherapy , except give part multimodal treatment locally advanced disease complete 2 month prior trial entry . Nasopharyngeal carcinoma . Medical history diagnose interstitial lung disease . Known hypersensitivity component trial treatment . Previous treatment experimental nonapproved epidermal growth factor receptor ( EGFR ) target therapy experimental nonapproved EGFR signal transduction inhibitor ( prior treatment cetuximab allow ) . Relevant cardiovascular comorbidities . Concomitant chronic systemic immune therapy , hormonal therapy cancer therapy , steroid use ≥ 10 mg prednisone equivalent . Known human immunodeficiency virus ( HIV ) positivity , active hepatitis C , active hepatitis B .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>maximum tolerate dose EMD 1201081</keyword>
	<keyword>TLR9 agonist</keyword>
	<keyword>squamous cell carcinoma head neck</keyword>
	<keyword>First line subject</keyword>
	<keyword>recurrent/metastatic</keyword>
</DOC>